跳至主要内容
临床试验/NCT04200625
NCT04200625已完成不适用

Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity

University of Miami1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年9月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
1
主要终点
Epicardial Fat thickness

研究概览

简要总结

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

详细描述

This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records.

Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes,
  • BMI ≥27 kg/m2,
  • Age ≥ 18 years old

排除标准

  • Type 1 diabetes
  • Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors
  • History of diabetic ketoacidosis
  • Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2
  • Acute infective diseases, cancer or chemotherapy
  • Use of systemic corticosteroids within the 3 months prior this study
  • Known or suspected allergy to semaglutide or dulaglutide excipients or related products
  • Pregnancy, breastfeeding or the intention of becoming pregnant

结局指标

主要结局

Epicardial Fat thickness

时间窗: 12 weeks

Ultrasound measured Epicardial Fat thickness

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gianluca Iacobellis

Professor of Medicine

University of Miami

研究点 (1)

Loading locations...

相似试验

已完成
4 期
Liraglutide Effects on Epicardial Fat Inflammatory GenesType2 DiabetesCoronary Artery Disease
NCT03260881University of Miami40
进行中(未招募)
1 期
Effect of Empagliflozin and Semaglutide on the Cardiovascular system and Kidneys in patients with type 2 diabetes – A randomized TrialMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Type 2 Diabetes Mellitus
EUCTR2019-000781-38-DKAarhus University Hospital120
进行中(未招募)
1 期
SELECT - Semaglutide effects on heart disease and stroke in patients with overweight or obesityOverweightObesityMedDRA version: 20.0Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2017-003380-35-IEovo Nordisk A/S17,500
进行中(未招募)
1 期
SELECT - Semaglutide effects on heart disease and stroke in patients with overweight or obesityOverweightObesityMedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2017-003380-35-BGovo Nordisk A/S17,500
进行中(未招募)
1 期
SELECT - Semaglutide effects on heart disease and stroke in patients with overweight or obesity
EUCTR2017-003380-35-ATovo Nordisk A/S17,500